Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
Adult
Aged
Aged, 80 and over
Autoantibodies
/ blood
Cyclophosphamide
/ therapeutic use
Follow-Up Studies
Glomerulonephritis, Membranous
/ blood
Humans
Immunosuppressive Agents
Middle Aged
Proteinuria
/ urine
Receptors, Phospholipase A2
/ immunology
Remission Induction
Retrospective Studies
Serum Albumin
/ analysis
Treatment Outcome
Young Adult
24h proteinuria
Idiopathic Membranous Nephropathy
PLA2R-Ab
cyclophosphamide
prediction
remission
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
25
02
2020
revised:
22
04
2020
accepted:
23
04
2020
pubmed:
26
5
2020
medline:
29
6
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
We aimed to evaluate cyclophosphamide efficacy in the treatment of idiopathic membranous nephropathy (IMN) and explore the efficacy of phospholipase-A2 receptor antibody (PLA2R-Ab), 24 hours proteinuria, and serum albumin in predicting 6- and 12-month treatment effects. A retrospective analysis was performed on 135 patients with IMN who followed up after treatment. The observation points were before, and after 3, 6, and 12 months of treatment. We collected clinical indicator data at each observation point and measured PLA2R-Ab levels before and after 3-month treatment. The remission rates at 3, 6, and 12 months of cyclophosphamide therapy for patients with IMN were 41.4, 74.8, and 76.1%, respectively. Patients in whom PLA2R-Ab turned negative within 3 months had high remission rates at 3, 6, and 12 months after treatment (P < .05). PLA2R-Ab change at 3 months had a strong correlation with 24 hours proteinuria change at 6 months. The change in albumin concentration before and after 3-month treatment was an independent variable related to remission rate at 6 months, and 24 hours proteinuria change before and after 6-month treatment was an independent variable related to remission rate at 12 months after treatment. Cyclophosphamide showed good efficacy at 3, 6, and 12 months for patients with IMN. Serum albumin change and PLA2R-Ab change at 3 months can be used as indicators to predict remission at 6 months, respectively. Moreover, 24 hours proteinuria change at 6 months can predict remission at 12 months.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to evaluate cyclophosphamide efficacy in the treatment of idiopathic membranous nephropathy (IMN) and explore the efficacy of phospholipase-A2 receptor antibody (PLA2R-Ab), 24 hours proteinuria, and serum albumin in predicting 6- and 12-month treatment effects.
METHODS
METHODS
A retrospective analysis was performed on 135 patients with IMN who followed up after treatment. The observation points were before, and after 3, 6, and 12 months of treatment. We collected clinical indicator data at each observation point and measured PLA2R-Ab levels before and after 3-month treatment.
RESULTS
RESULTS
The remission rates at 3, 6, and 12 months of cyclophosphamide therapy for patients with IMN were 41.4, 74.8, and 76.1%, respectively. Patients in whom PLA2R-Ab turned negative within 3 months had high remission rates at 3, 6, and 12 months after treatment (P < .05). PLA2R-Ab change at 3 months had a strong correlation with 24 hours proteinuria change at 6 months. The change in albumin concentration before and after 3-month treatment was an independent variable related to remission rate at 6 months, and 24 hours proteinuria change before and after 6-month treatment was an independent variable related to remission rate at 12 months after treatment.
CONCLUSION
CONCLUSIONS
Cyclophosphamide showed good efficacy at 3, 6, and 12 months for patients with IMN. Serum albumin change and PLA2R-Ab change at 3 months can be used as indicators to predict remission at 6 months, respectively. Moreover, 24 hours proteinuria change at 6 months can predict remission at 12 months.
Identifiants
pubmed: 32449206
doi: 10.1002/jcla.23368
pmc: PMC7521260
doi:
Substances chimiques
Autoantibodies
0
Immunosuppressive Agents
0
Receptors, Phospholipase A2
0
Serum Albumin
0
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23368Subventions
Organisme : National Science and Technology Major Project of China
ID : 2018ZX10302205
Organisme : Guangdong Province Major key projects of industrial technology
ID : 201902010003
Organisme : Liaoning Province Central Government's special project to guide local scientific and technological development
ID : 2019JH6/ 10400009
Organisme : "345 talent project" of Shengjing Hospital of China Medical University
Organisme : Major Special Project of Construction Program of China Medical University in 2018
ID : 112/3110118034
Organisme : Liaoning Province Natural Science Foundation Project
ID : 20180550523,2019-ZD-0752
Informations de copyright
© 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC.
Références
J Am Soc Nephrol. 2017 Feb;28(2):421-430
pubmed: 27777266
Biomarkers. 2015 Feb;20(1):77-83
pubmed: 25519165
Med Sci Monit. 2016 May 15;22:1630-6
pubmed: 27179439
Autoimmun Rev. 2016 Feb;15(2):146-54
pubmed: 26527329
PLoS One. 2013 Apr 26;8(4):e62151
pubmed: 23637987
Clin Transplant. 2016 Apr;30(4):461-9
pubmed: 26854647
Chin Med J (Engl). 2017 Apr 20;130(8):892-898
pubmed: 28397717
Ren Fail. 2019 Nov;41(1):673-681
pubmed: 31354007
Ethiop J Health Sci. 2018 Nov;28(6):711-716
pubmed: 30607087
Kidney Int. 2015 Jun;87(6):1263-4
pubmed: 26024039
Autoimmun Rev. 2017 Feb;16(2):136-145
pubmed: 27988429
Am J Nephrol. 2016;43(2):129-40
pubmed: 27058841
J Transl Med. 2019 Feb 8;17(1):41
pubmed: 30736804
N Engl J Med. 2014 Dec 11;371(24):2277-2287
pubmed: 25394321
Semin Nephrol. 2003 Jul;23(4):324-32
pubmed: 12923720
N Engl J Med. 2009 Jul 2;361(1):11-21
pubmed: 19571279
Kidney Int. 2012 Oct;82(8):840-56
pubmed: 22895519
Clin Kidney J. 2017 Aug;10(4):450-454
pubmed: 28852480
BMC Nephrol. 2019 Sep 18;20(1):360
pubmed: 31533641
Clin J Am Soc Nephrol. 2008 May;3(3):905-19
pubmed: 18235148
PeerJ. 2020 Feb 21;8:e8650
pubmed: 32117644
J Am Soc Nephrol. 2011 Aug;22(8):1543-50
pubmed: 21784898
J Clin Lab Anal. 2020 Sep;34(9):e23368
pubmed: 32449206
Nephron. 2017;135(2):87-96
pubmed: 27974710
Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1386-92
pubmed: 25035272